Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

Polycystic Ovarian Syndrome Clinical Trial

— ATTAC-PCO  

Official title:

A Phase IIIb Randomized Open-label Study to Compare the Estradiol Level on the Releasing Day in Two Regimen of Cetrotide® 0.25 mg Used From Day 1 or From Day 7 of the Menstrual Cycle (Day 0 or Day 6 of Stimulation) in Polycystic Ovarian (PCO) Women in ART (IVF/ICSI).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01185704
• Other study ID #: EMR200088-501
• Secondary ID: 2007-007932-25IN
• Status: Completed
• Phase: Phase 3
• First received: August 10, 2010
• Last updated: January 20, 2014
• Start date: November 2008
• Est. completion date: February 2012

Study information

• Verified date: January 2014
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

This is a randomized open-label study to compare between in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes of the two regimen of Cetrotide® (Cetrorelix acetate) which are 0.25 milligram (mg) used from Day 1 or Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in assisted reproductive technology (ART).

Description:

Polycystic ovarian syndrome population is an androgenic syndrome characterized by a wide spectrum of clinical manifestations such as obesity, hirsutism, insulin resistance, diabetes and presence of specific ultrasonic features.

Cetrotide®, cetrorelix acetate, is an antagonist of luteinizing-hormone-releasing hormone (LHRH). Cetrotide® is registered in 70 countries (including France) for the prevention of premature ovulation in subjects undergoing a controlled ovarian stimulation, followed by oocyte pick-up and ARTs. Ovitrelle®, active ingredient human chorionic-gonadotropin alfa, is administered to trigger final follicular maturation and luteinization after stimulation of follicular growth.

OBJECTIVES

Primary objective:

• To compare the hormonal level of plasmatic estradiol on the releasing day (day of r-hCG administration) induced by Cetrotide® 0.25 mg/day started on Day 1 (Group A: Day 1) or on Day 7 (Group B: Day 7) of the menstrual cycle (Day 0 (S0) or Day 6 (S6) of stimulation) in PCO subjects undergoing IVF/ICSI procedures.

Secondary objectives:

• To compare the hormonal changes during the stimulation induced by Cetrotide® in A and B Groups

• To assess by ultrasound scans (US) the follicular development induced by Cetrotide® in A and B Groups

• To assess biological and clinical outcomes induced by Cetrotide® in A and B Groups

• To monitor safety of Cetrotide in A and B Groups

The trial will be conducted on an outpatient basis. Once each subject has met all eligibility criteria, they will be randomly assigned in one of the two treatment groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 136
• Est. completion date: February 2012
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Female subjects with PCO or Polycystic ovary syndrome (PCOS) according to the revised 2003 Rotterdam Consensus

• Female subjects suitable for IVF/ICSI, undergoing first or second attempt

• 18-35 years old, Body Mass Index (BMI) less than or equal to 32, non-smoking at least from Visit 0 (V0)

• Normal FSH value (less than 10 international unit per liter [IU/L]) on Day 3 of spontaneous cycle within 12 months prior to the trial

• Anti Mullerian Hormone (AMH) value (greater than 1.5 nanogram per milliliter [ng/mL]) of a spontaneous cycle within 12 months prior to the trial or at least at V0

• No history of active genito-urinary infection

• Normal thyroid function (or adequate substitution for at least 3 months)

• Negative cervical papanicolaou test within the last 12 months prior to study entry

• No gonadotropins, for at least one month prior to the trial

• No metformin therapy for at least one month prior to Visit 1 (V1)

• Subject who is able to participate in the trial and has provided written, informed consent.

Exclusion Criteria:

• Ongoing pregnancy, any pregnancy within 3 months prior to study entry, or any contraindication to pregnancy or carrying pregnancy to term

• Drilling 3 months prior to V0

• Uterine malformation, diethylstilbestrol syndrome, synechia

• Female subjects with World Health Organization (WHO) Type I or III anovulation

• Female subjects with hyperprolactinemia

• Female subjects with more than 2 recurrent miscarriages (early or late, and for any reasons)

• Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus, for subject or partner

• Abnormal gynecological bleeding of undetermined origin

• History of major thromboembolic disease

• Endometriosis (Grade III or IV)

• Presence or history of malignant tumors and related treatment

• Known case of tumors of the hypothalamus or pituitary gland

• Clinically significant systemic disease or clinically significant abnormal hematology, chemistry, or urinalysis results at screening

• Known allergic reaction or hypersensitivity to Cetrotide® or Ovitrelle®

• Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years

• Participation in another clinical trial within 3 months prior to study entry.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Polycystic Ovarian Syndrome
• Polycystic Ovary Syndrome

Intervention

Drug:
• Cetrorelix acetate
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
• Cetrorelix acetate
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
• Recombinant Human Choriogonadotropin (r-hCG)
The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
• Recombinant human follicle stimulating hormone (r-hFSH)
Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day

Locations

Country	Name	City	State
France	Research Site	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
Merck KGaA	Merck Serono S.A.S, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estradiol (E2) Levels on r-hCG Day		r-hCG day (end of stimulation cycle [approximately 15 days])	No
Secondary	Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Levels		Day 1	No
Secondary	Serum Estradiol (E2) Levels		Day 1	No
Secondary	Serum Progesterone (P4) Levels		Day 1	No
Secondary	Anti Mullerian Hormone (AMH) Levels		Day 0	No
Secondary	Number of Follicles Greater Than or Equal (>=) to 17 mm (For Day 1 Protocol) or 19 mm (For Day 7 Protocol) on r-hCG Day		r-hCG day (end of stimulation cycle [approximately 15 days])	No
Secondary	Number and Quality of Oocytes Retrieved	Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body. Oocytes were classified into 4 different categories based on their quality: mature, fractured, immature and inseminated oocytes.	Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])	No
Secondary	Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)		Day 1 up to r-hCG day (end of stimulation cycle [approximately 15 days])	No
Secondary	Percentage of Fertilized Oocytes Retrieved	Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an IVF procedure in which a single sperm is injected directly into an egg under a microscope.	Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])	No
Secondary	Number of Embryos	Embryo is defined as the product of the zygote, two or three days after fertilization of the oocytes.	Day 2-3 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])	No
Secondary	Number of Blastocysts	Blastocyst is an embryo, five or six days after fertilization, with an inner cell mass, outer layer of trophectoderm and a fluid-filled blastocoele cavity.	Day 5-6 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])	No
Secondary	Number of Transferred Embryos	Embryo transfer is the procedure in which one or more embryos are placed in the uterus.	Day 2-3 post Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])	No
Secondary	Implantation Rate	Implantation rate per reporting group was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.	5 weeks post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])	No
Secondary	Percentage of Participants With Clinical Pregnancy	Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy.	10 weeks post r-hCG day (end of stimulation cycle [approximately 15 days])	No
Secondary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. To avoid the participant/event combination double-count AEs and SAEs are reported separately.	Day 1 up to end of study (15 days post last administration of study drug)	Yes